An inverse agonist at CB2 and partial agonist at CB1 receptors 5 mg

Description

AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.1 AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.1,2,3 It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.4WARNING This product is not for human or veterinary use.